Connect with us

Media & Technology

Flagship”Sweet Virginia” Expands Production; the Story of American Green Inc (OTCMKTS: ERBB)

Published

on

American Green Inc (OTCMKTS: ERBB) is making a powerful run in recent weeks off its triple zero lows to highs near a penny. The stock has emerged as a volume leader as Arizona legalized cannabis for recreational use. American Green’s “Sweet Virginia” Cannabis Grow Operation recently surpassed $3,000,000 in total sales revenues since opening and is operating profitably. ERBB management division was given the green light to expand its current cannabis production by 300% in 2021.  The current grow management in Phoenix, at the company’s flagship operation “Sweet Virginia,” have proven successful in both profitability and in developing a well-earned reputation producing consistently high-quality cannabis in high demand.

Marijuana and CBD stocks are on the rise in recent months as New Jersey, Arizona, Montana and South Dakota legalize cannabis for recreational use. Also the house just passed sweeping legislation that would decriminalize marijuana and expunge nonviolent marijuana-related convictions although the bill is unlikely to pass. CBD is booming and is projected to reach $4.7 billion in US sales in 2020 up from $4.1 billion in 2019. According to a new reported from reserchandmarkets.com; The U.S. cannabidiol market is estimated to reach US$13.39 billion in 2024, growing at a CAGR of 42.36% for the period spanning 2020-2024.

American Green Inc (OTCMKTS: ERBB) operating out of Phoenix, Arizona became, in 2009, America’s second publicly-traded company in the cannabis industry. The Company operates a 12,000 sq. ft. Phoenix indoor grow operation it calls “Sweet Virginia.” American Green now, with its more than 50,000 certified beneficial shareholders, is one of the largest (in shareholder count)  in the cannabis sector. American Green’s mission is to lead the cannabis and premium CBD industry. Leveraging our team of professionals in cultivation management, manufacturing, extraction, wholesale, retail, and community outreach, we strive to develop sustainable initiatives in the cannabis-adjacent and CBD industries, laser-focused on adding company and shareholder value.

The American Green CBD Emporium is well stocked with some very high quality CBD offerings – all at very reasonable prices with its Thanksgiving Specials. Check out American Green’s newest product offerings including its: 50mg CBD Capsules (Sleep Formula), 25mg Water Soluble Powder (10 Pack) and our 1000mg CBD Balm. Or, shop our top selling products (based on order frequency) which include our CBD Capsules, CBD Oils and CBD Pet Treats. Why Shop American Green? Free Shipping On All Orders. Large Selection of Products (over 140 items and growing) 100% USA Made Products. All Products are THC-FREE (they contain 0.00% THC). 20% Discount For Shareholders (promo code INVESTOR). Weekly Deals (new deals every week). American Green accepts: Visa, MasterCard, American Express, Discover, and Diners Club (which are securely processed in the USA).

To Find out the inside Scoop on ERBB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ERBB

Earlier this year ERBB reported its largest smart vending machine customer, EZ Weed, has hit the ground running with their current nationwide sales team who provide dispensaries and CBD shops with the ability to better serve their customers using the revolutionary Smart Vending Kiosk developed by American Green in association with their independent technology partner, PanPacific International. EZ Weed’s current order of 20 machines are fully paid for and production is underway.

American Green’s “Sweet Virginia” Cannabis Grow Operation has just surpassed $3,000,000 in total sales revenues since opening and is operating profitably. ERBB management  division was given the green light to expand its current cannabis production by 300% in 2021.  The current grow management in Phoenix, at the company’s flagship operation “Sweet Virginia,” have proven successful in both profitability and in developing a well-earned reputation producing consistently high-quality cannabis in high demand. The Company has begun vetting qualified locations in Arizona. Once the new site is outfitted and permitted to begin growing, ERBB plans to export the same successful grow management techniques we employ at the ‘Sweet Virginia’ grow in Phoenix.  By doing so, American Green should produce consistently high quality cannabis which the Company believes will lead to high demand for our superior product, and duplicate the success we experienced at the Sweet Virginia Grow over the past several years.”

According to its grow division manager, American Green doesn’t just grow cannabis…the company delivers some of the best cannabis available in Arizona on behalf of its licensor.  With few exceptions (for security purposes) the American Grow Operation can be viewed LIVE every weekday by going to https://americangreen.com/live/  on your web browser.

https://twitter.com/GainsDayTrades/status/1335756806229012483

 

For More on ERBB Subscribe Right Now!

ERBB is making a powerful run in recent weeks off its triple zero lows to highs near a penny. The stock has emerged as a volume leader as Arizona legalized cannabis for recreational use. American Green’s “Sweet Virginia” Cannabis Grow Operation has just surpassed $3,000,000 in total sales revenues since opening and is operating profitably. ERBB management division was given the green light to expand its current cannabis production by 300% in 2021.  The current grow management in Phoenix, at the company’s flagship operation “Sweet Virginia,” have proven successful in both profitability and in developing a well-earned reputation producing consistently high-quality cannabis in high demand. Marijuana and CBD stocks are on the rise in recent months as New Jersey, Arizona, Montana and South Dakota legalize cannabis for recreational use. Also the house just passed sweeping legislation that would decriminalize marijuana and expunge nonviolent marijuana-related convictions although the bill is unlikely to pass. CBD is booming and is projected to reach $4.7 billion in US sales in 2020 up from $4.1 billion in 2019. According to a new reported from reserchandmarkets.com; The U.S. cannabidiol market is estimated to reach US$13.39 billion in 2024, growing at a CAGR of 42.36% for the period spanning 2020-2024. Microcapdaily has been reporting on ERBB for years including the time ERBB ran from triple zero subs to over $0.10; this Company knows how to get their brand into the national media. We will be updating on ERBB on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with ERBB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ERBB either long or short and we have not been compensated for this article.

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.